Elanco Animal Health Incorporated
ELAN
Rangering i aksjer
#1873
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces,... Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Aksjekurs
$22.70
Sist synkronisert: 2026-10-20
Markedsverdi
$11.34B
Endring (1 dag)
-3.45%
Endring (1 år)
4.97%
Land
US
Handel Elanco Animal Health Incorporated (ELAN)
Kategori
Healthcare
Inntekter for Elanco Animal Health Incorporated (ELAN)
Inntekter i Jun 2026 TTM: $-166.00M
Ifølge Elanco Animal Health Incorporated sine nyeste økonomiske rapporter er selskapets nåværende resultat $-166.00M. I 2023 hadde selskapet et resultat på $-1.20B, en nedgang sammenlignet med resultatet i 2022, som var $-72.00M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Elanco Animal Health Incorporated fra 2015 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $-166.00M | -134.02% |
| 2024 | $488.00M | -140.84% |
| 2023 | $-1.20B | 1,559.72% |
| 2022 | $-72.00M | -87.39% |
| 2021 | $-571.00M | -15.03% |
| 2020 | $-672.00M | -959.34% |
| 2019 | $78.20M | -31.46% |
| 2018 | $114.10M | -149.05% |
| 2017 | $-232.60M | 938.39% |
| 2016 | $-22.40M | -91.37% |
| 2015 | $-259.50M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -1,162.98% |
IN
|
